PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 27(Supplement_2): 272-280
2007
© 2007 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, S. S.Y.
Right arrow Articles by Yuen, K.-Y.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wong, S. S.Y.
Right arrow Articles by Yuen, K.-Y.

Part 8: PD Peritonitis

EVOLUTION OF ANTIBIOTIC RESISTANCE MECHANISMS AND THEIR RELEVANCE TO DIALYSIS-RELATED INFECTIONS

Samson S.Y. Wong, Pak-Leung Ho and Kwok-Yung Yuen

Department of Microbiology, Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, PR China

Correspondence to: K.Y. Yuen, Department of Microbiology, The University of Hong Kong, 4/F University Pathology Building, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, PR China. hkumicro{at}hkucc.hku.hk

As the survival of patients with end-stage renal failure has improved, their exposure to antibiotics has also increased. Infections, especially peritoneal dialysis–related peritonitis, are unavoidable because of lapses in technique and the slow worsening of systemic and peritoneal defense associated with aging and dialysis. The selective pressure inherent in the use of antibiotics shapes the pattern of antibiotic resistance in the bacteria causing peritonitis and extraperitoneal infections, and vice versa.

Renal function–preserving and non-ototoxic regimens that incorporate double β-lactams (first- and third-generation cephalosporins) for peritonitis have increased the selective pressure in favor of methicillin-resistant staphylococci (MRS) and extended-spectrum β-lactamase (ESBL)–producing Enterobacteriaceae. Attempts to use the fluoroquinolones as alternatives to β-lactams was met with rocketing quinolone resistance. The high incidence of MRS led many nephrologists to use empiric vancomycin—until the début of vancomycin-resistant enterococci. The recent emergence of heterogeneous and high-level vancomycin resistance in staphylococci (which are especially prevalent in patients on dialysis) calls for further prudence in the use of vancomycin.

The coming challenges are ESBL-producing Enterobacteriaceae with carbapenemase, multi-resistant Pseudomonas, and highly virulent community-acquired methicillin-resistant Staphylococcus aureus with Panton–Valentine leukocidin. Antibiotic auditing programs and meticulous patient training by nurses are the only available defense at the moment. Novel approaches such as antibiotic-impregnated Tenckhoff catheters, biocompatible dialysis fluid, and peritoneal immuno-augmentation strategies are eagerly awaited.

KEY WORDS: Antibiotic resistance; antibiotic control; vancomycin-resistant Staphylococcus aureus; vancomycin-resistant enterococci; extended-spectrum beta-lactamase; carbapenemase; peritonitis.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2007 by Multimed Inc.